Automate Your Wheel Strategy on RMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RMD
- Rev/Share 35.1352
- Book/Share 40.744
- PB 6.572
- Debt/Equity 0.1478
- CurrentRatio 3.4398
- ROIC 0.195
- MktCap 39205544550.0
- FreeCF/Share 11.3246
- PFCF 23.6359
- PE 28.0004
- Debt/Assets 0.1079
- DivYield 0.0082
- ROE 0.2551
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RMD | CLSA | Hold | Outperform | -- | -- | Sept. 2, 2025 |
| Upgrade | RMD | RBC Capital Mkts | Sector Perform | Outperform | -- | $294 | July 15, 2025 |
| Initiation | RMD | Morgan Stanley | -- | Overweight | -- | -- | March 19, 2025 |
| Initiation | RMD | Goldman | -- | Buy | -- | -- | Jan. 16, 2025 |
| Initiation | RMD | Piper Sandler | -- | Neutral | -- | $252 | Jan. 10, 2025 |
| Initiation | RMD | Stifel | -- | Hold | -- | $250 | Dec. 13, 2024 |
| Initiation | RMD | Robert W. Baird | -- | Outperform | -- | $280 | Sept. 24, 2024 |
| Downgrade | RMD | Wolfe Research | Peer Perform | Underperform | -- | $180 | Sept. 18, 2024 |
News
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Read More
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Jan De Witte joins GHO Capital as Operating Partner
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies.
Read More
About ResMed Inc. (RMD)
- IPO Date 1995-06-02
- Website https://www.resmed.com
- Industry Medical - Instruments & Supplies
- CEO Michael J. Farrell BE, MBA, SM
- Employees 9980